Combinations, Proper Sequencing Needed for Optimal HR+ Breast Cancer Treatment
William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.
TNBC Subgroup Stands to Benefit From Androgen Receptor Antagonists
Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.
Treatment Paradigm for TNBC Continues to Evolve
With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.
Expert Describes Potential Therapeutic Vaccine for Advanced HCC
Ghassan K. Abou-Alfa, MD, discusses research into the use of the immunotherapeutic vaccinia virus Pexa-Vec as a frontline treatment for advanced hepatocellular carcinoma.
Large Analysis Sheds Light on Risk Factors for Non-Cirrhotic NASH-Associated HCC
About one quarter of patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma present without cirrhosis at diagnosis, suggesting a crucial subset of patients for future research with implications for HCC screening and surveillance.
Regorafenib Poised as Second-Line Standard of Care in HCC
Although regorafenib is not currently approved, Morris Sherman, MD, PhD, already views the agent as the standard second-line therapy, with hopes for moving the agent into the frontline setting.
Midostaurin Shows Promise in Advanced Mastocytosis Trial
The multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate of 60% in patients with advanced systemic mastocytosis.
FDA Approves Dronabinol Solution to Treat CINV
A dronabinol oral solution (Syndros) has been approved by the FDA as a treatment for patients with chemotherapy-induced nausea and vomiting (CINV) in those who have not responded to conventional antiemetic therapies.
Early Integration of Palliative Care Improves Outcomes for Family Caregivers
Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.
Proactive, Team-Based Approach Leads to Better Care, Fewer Treatment Delays for Head and Neck Cancer Patients
A multidisciplinary team led by oncology nurses can reduce both hospitalization and treatment breaks for patients with head and neck cancer.
Phone Calls May Help Assess, Improve Oral Cancer Therapy Adherence
With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.
Optimizing Current Treatments for CLL as New Agents Are Investigated
Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.
“Forgotten Lessons” May Help Advance Colorectal Cancer Care
Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.
TILs Advancing as Melanoma Immunotherapy Option
After nearly 30 years of research,
is being investigated as a
means of producing personalized
immunotherapy for patients with
metastatic melanoma in a small
clinical trial that may help open
the door for broader application in
other solid tumor types.
Expert Discusses Emerging Agents in ER+ Metastatic Breast Cancer
MD, discusses how four agentsâ€”palbociclib (Ibrance), pembrolizumab (Keytruda),
abemaciclib (LY2835219), and buparlisib (BKM120)â€”are worth examining in estrogen receptor-positive breast cancer.
World Cancer Day Aims to Unite Millions to Increase Awareness, Reduce Global Burden
With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.
Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma
Combining olaratumab with doxorubicin reduced the risk of death by 54% versus doxorubicin alone in patients with advanced soft tissue sarcoma.
New Model Supports Use of Palliative Care With Radiotherapy for Bone Metastases
A novel service model that incorporated palliative care measures and shorter radiation treatment was associated with fewer unfinished treatments with radiation, shorter hospital stays, and increased use of palliative care for patients with bone metastases.
June Provides Insight Into Managing AEs From CAR T-Cell Therapies
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy
Large Study Adds Clarity to Use of Docetaxel With Standard Care in Advanced, Hormone-NaÃ¯ve Prostate Cancer
The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naÃ¯ve advanced prostate cancer.
Experts Offer Insight on BRCA1/2 Testing and Prophylactic Procedures
Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.
Oncology Nurses Poised to Make a Difference in Managing “Silent” Portal Vein Thrombosis
Portal vein thrombosis is a dangerous and often overlooked side effect of certain gastrointestinal malignancies such as liver and pancreatic cancer, that oncology nurses need to be more proactive in managing.
CAR T-Cell Therapy Surpasses 90% Complete Remission Rate in Pediatric ALL
The chimeric antigen receptor T-cell therapy JCAR017 elicited a 91% complete remission rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial
Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.
Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma
IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.
Challenges, Need for New Therapies Remain in HCC
To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.
Frontline Pembrolizumab Bests Ipilimumab in Phase III Melanoma Trial
A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints
Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy
First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.
Expert Discusses Frontline Bortezomib in MCL
To gain new insight on the phase III LYM-3002 study and bortezomib's use in the frontline MCL setting, OncLive interviewed Andrew Evens, DO, MSc, director of the Tufts Cancer Center and chief of the Division of Hematology/Oncology at Tufts University School of Medicine.
FDA Accepts NDA for New Formulation of Melphalan for Myeloma
The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).
Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer
Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC
Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS
2 Clarke Drive Cranbury, NJ 08512